Preclinical Capabilities

Cell Therapy/Immuno-Oncology Preclinical Models

Trusted immune-oncology models for optimal CAR-T study design

TD2 is your trusted, experienced team when it comes to running preclinical Adoptive Cell Transfer Therapy studies. Our extensive knowledge of CAR-T in both solid and hematologic tumors enables optimal study design and rapid study initiation.

Not only can we execute your preclinical studies, but we provide a consultative approach to ensure best results and continuity with a clinical and regulatory strategy. Having performed hundreds of studies and strong experience with CAR T-cell handling and processing, we have the specialized oncology knowledge to design and execute your preclinical program in support of your clinical and regulatory goals.

TD2 can begin with cryopreserved or fresh CAR T-cells. We use fluorescent-based counting methods rather than manual dye counting to learn more about the viability of the CAR T-cells. Fluorescent counting helps to more accurately determine cell count and viability.

Cell Therapy Capabilities of 400+ Cell line derived xenograft (CDX) models include:

  • Optical imaging (Bioluminescence and Fluorescence)
  • Orthotopic and surgical
  • IP Dissemination
  • IV Dissemination
  • Hematological
  • Biodistribution
  • Non-GLP Toxicity

Learn more about our CAR-T services.

Contact our experts to help advance your adoptive cell therapy with our trusted preclinical research services.

    Figure A. CAR-T Cell Treatment on subQ Hs7666T
    Pancreatic Cell Line. 5 x 106 CAR-T Cells given on Day 1
    Figure B. CAR-T Cell Treatment on IV disseminated
    Nalm-6-luc ALL Cell Line. 4 x106 CAR-T Cells given on Day 4

    Available Cell Lines

    786-0 Human Renal Cell Carcinoma KKU-M213 human intrahepatic cholangiocarcinoma
    A2780: Human Ovarian MCF-7 Human Breast
    A498: Human Renal Cell Carcinoma MM1.s Human Multiple Myeloma
    ACHN Renal Cell Adenocarcinoma Nalm6-Fluc-GFP Acute Lymphoblastic Leukemia
    BxPC3 Human Pancreas Nalm-6 Human Acute Lymphoblastic Leukemia
    Caki-1 Human Renal Cell Carcinoma NCI-H660 Human Prostate Neuroendocrine
    Caki-2 Human Renal Cell Carcinoma NCI-H1963 Human Lung
    CCRF-CEM Human Acute T Cell Lymphoblastic Leukemia NCI-H1975 Human Non-Small Cell Lung
    H69 Human Small Cell Lung NCI-N87 Human Gastric
    H209 Human Lung OV90 Human Ovarian
    HCC70 Human Breast OVCAR-3 Human Ovarian
    HCC1954 Human Breast Raji Human Burkett’s Lymphoma
    HCT116 Human Colon RPMI-8226 Human Myeloma
    HH Human Cutaneous T Cell Lymphoma SKOV-3 Human Ovarian
    Hs766T Human Pancreas SNU-1 Human Gastric Carcinoma
    HT-55 Human Colorectal SW-480 Human Colon
    HuT78 Human Cutaneous T Lymphocyte SW-620 Human Colon
    Jeko-1 Human Mantle Cell Lymphoma THP-1 Human Acute Myeloid Leukemia
    Jurkat-Luc Human Acute T Cell Leukemia Toledo Human Diffuse Large B-Cell Lymphoma

    TD2 has been an extremely valuable and flexible partner for CRISPR Therapeutics, performing many CAR-T cell mouse studies across multiple antigen targets in a number of oncology indications.

    • Dr. Jon TerrettHead of Immuno-Oncology Research and Translation CRISPR Therapeutics

    Immuno-oncology

    Comprehensive preclinical services for immuno-oncology.

    TD2’s extensive knowledge of CAR-T in both solid and hematologic tumors enables rapid evaluation of your CAR-T cell therapy, moving your therapeutic program forward to the clinic.

    Large panel of human and murine tumor models

    Syngeneic mouse models


    • Fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors

    Humanized mice


    • Human PBMCs or effector cell engraftment
    • Sourced CD34+ humanized mice

    Get Started

    Work with a team who believes in your research as much as you do.

    Are you ready to start your preclinical Adoptive Cell Transfer Therapy studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.